Pregnancy does not affect fecal calprotectin concentration in healthy women
Noninvasive activity markers for the evaluation of disease activity in pregnant women suffering from IBD in whom endoscopy should not be performed would have significant clinical relevance. However, as there are no data available on the changes in FC during normal pregnancy, we aimed to assess FC concentration in healthy pregnant and non-pregnant women.
MATERIALS AND METHODS
Between January 2013 and January 2016, 24 healthy women [controls without any bowel disease and women undergoing in vitro fertilization cycles (mean age: 33.1 years, SD: 5.2 years)], 48 healthy pregnant women (pregnant subjects without any bowel disease; mean: 35.9 years, SD: 5.2 years) were enrolled in this prospective study. The second control group consisted of 40 women with active IBD (mean: 39.6 years, SD: 15 years) and 23 women with IBD in sustained clinical remission (mean: 42.0 years, SD: 13.9 years) ( Table 1 ). The clinical activity of IBD was assessed with partial Mayo (pMayo) (4,5) score in ulcerative colitis (UC) patients and with Crohn' s Disease Activity Index (CDAI) in Crohn' s disease (CD) patients. Endoscopy was excluded from the full Mayo score. FC and serum C-reactive protein (CRP) measurements were performed in all participants to assess the effect of pregnancy on FC concentrations and CRP levels. Stool samples were collected from the first bowel movement in the morning. Fecal samples for FC determination were stored at −20°C until analysis. Fecal specimens were thawed and prepared for FC assay as described by the manufacturer. FC concentrations were measured with a quantitative lateral flow assay (Quantum Blue, Bühlmann Laboratories, Switzerland).
Statistical Analysis
Statistical analyses were performed using R statistical program (version 3.2.4). Descriptive parameters were shown as mean (SD) and/or median (range). The Mann-Whitney U test and Kruskal-Wallis test followed by post-hoc tests were used to analyze FC concentrations and CRP levels within groups. The post-hoc pairwise comparisons (if required) were performed according to the Bonferroni-Holm method. A p value of <0.05 was considered statistically significant.
Ethics
The study was approved by the Regional and Institutional Human Medical Biological Research Ethics Committee of the University of Szeged (ethical approval number: SZTE-170/2011). The study conforms to the declaration of Helsinki. All study participants, or their legal guardian, provided written informed consent prior to study enrolment.
RESULTS

Healthy Female Controls without IBD
The mean FC concentration was 34.1 μg/g (median: : 25 μg/g, SD: 27.5 μg/g, range: 25.0-150.0 μg/g) in healthy controls. In healthy controls, we found five patients with gynecological diseases (endometriosis, myoma uteri, and PCOS), two patients with hypothyreosis, one with hypertonia, and one with pancreas divisum. A significant difference (p<0.001) in FC concentrations was shown between patients with IBD (median: 298 μg/g, mean: 788.0 μg/g, SD: 1215.0 μg/g, range: 25.0-5000.0 μg/g) and healthy controls (median: 25 μg/g, mean: 36.0 μg/g, SD: 23.0 μg/g, range: 25.0-3000.0 μg/g).
Pregnant Subjects
In the pregnant subpopulation, 20 samples were from women in their first trimester, 11 samples were from women in the second, and 27 samples were from women in the third. Stool samples were collected from 10 of 48 pregnant subjects in the first, second, and third trimester. Ten gemini gravidities, two Rh-incompatibilities, and four other obstetric disorders were observed. In the pregnant group, four subjects had hypothyreosis, five had diabetes mellitus, three had hypertension, one had asthma, and one had hypercholesterinemia. With regard to FC concentration, healthy controls and pregnant subjects with the abovementioned diseases (median: 28 μg/g, mean: 40.0 μg/g, SD: 24.0 μg/g, range: 25.0-3000.0 μg/g) were compared with healthy controls and pregnant pa- (Table 2) . We did not find significant difference (p<0.092) between FC con- Original Article centrations in different trimesters during pregnancy ( Figure 1) . Overall, the mean FC concentration was 36.9 μg/g (median: 25 μg/g, SD: 20.4 μg/g, range: 25.0-3000 μg/g) in pregnant women and did not differ significantly from that of non-pregnant healthy women (p=0.99). One gemini pregnant woman without IBD had outstandingly high FC concentration (3000 ug/g). She was diagnosed with Rh-incompatibilities (mother: A Rh-negative, "A fetus": AB Rh-negative, "B fetus": A Rh-positive); in addition, she had type I diabetes mellitus. After delivery, we could not follow her up.
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Female Patients with IBD
Among IBD patients, 36 had CD and 27 UC. The majority of patients (n=54) were under treatment at the time of study enrolment (Table  3) . Eight active and one inactive IBD patients did not undergo therapy; however, these active IBD patients were previously in remission and came to consultation due to flare-up of symptoms. The mean CDAI was 211.7 points (SD: 73.5 points) in active CD and 87 points (SD: 26.7 points) in inactive CD. The mean pMayo subscore 108.5 μg/g, SD: 91.3 μg/g, range: 25.0-300.0 μg/g) in active and inactive UC patients, respectively. FC concentration was significantly higher in active IBD patients than in pregnant (p<0.001) and non-pregnant healthy women (p<0.001). Our results showed no significant difference between FC concentrations of inactive IBD patients and healthy controls (p=0.99). Furthermore, no significant difference was revealed between FC concentrations of inactive IBD patients and pregnant women (p=0.99).
CRP in Assessed Subgroups
Mean CRP levels were 6. 38) ; however, we found that patients with active IBD have significantly higher CRP levels than pregnant women (p<0.01).
DISCUSSION
In this prospective study, we aimed to confirm whether FC concentration changes during pregnancy and found that it did not differ between non-pregnant and pregnant women (Figure 2 ). Levels of inflammatory markers are commonly modified in pregnancy; however, FC and CRP may be useful indicators of relapse in IBD during pregnancy. Mechanisms such as anabolic metabolism and changes in hepatic and renal clearance result in physiological changes of laboratory parameters (6) . Hemodilution can explain changes in hemoglobin and albumin levels, and these parameters may decreases with progression of pregnancy (7). Iron deficiency is also common and should not be used as a marker of blood loss (7). Erythrocyte sedimentation rate (ESR) is commonly accelerated, and physiological leukocytosis is up to 15000 cells/μL (6) . On the other hand, noninvasive techniques have great use in defining disease activity in IBD during pregnancy due to the limited use of endoscopic procedures in this population. Recently, FC is one of the most important markers of relapse, and our results confirmed that FC was significantly higher in active IBD than in healthy pregnant and non-pregnant women.
Maternal CRP level has been extensively studied as a marker of inflammation among pregnant women; however, the utility of CRP can only be assessed if effects of normal pregnancy on CRP are established. Watts et al. found no consistent changes in CRP levels with gestational age (8), although CRP level has been reported to be higher in pregnancy, even in uncomplicated cases (9). We did not find any difference in CRP levels between pregnant and non-pregnant patients. Several additional analyses have been conducted to examine the associations between CRP and pre-eclampsia/eclampsia. CRP level was higher in established pre-eclampsia than in normal pregnant women (10); furthermore, higher CRP level was reported as an independent factor of pre-eclampsia (11); therefore, it should be taken into consideration when using CRP as a biomarker.
Serum calprotectin as an indicator of systemic inflammatory response was previously evaluated in complicated pregnancies, such as those accompanied by hypertension, pre-eclampsia, and diabetes mellitus. Sugulle et al. (12) reported significant difference in median plasma calprotectin concentrations between healthy subjects and women with gestational diabetes mellitus, and serum calprotectin was elevated in pre-eclampsia as well. Serum CRP level was higher in patients with gestational diabetes than in controls. Calprotectin analysis may be more favorable from fecal samples. Jost et al. (13) assessed microbiota composition with quantitative polymerase chain reaction and pyrosequencing in healthy subjects in the pre-and post-partum period, and results demonstrated that maternal microbiota remained stable over the perinatal period with only low-grade inflammation shown by FC levels.
In recent years, a few studies assessed the utility of FC in IBD during pregnancy, most of which were not published as full papers (14) (15) (16) (17) ; however, more and more data reported indicate the importance of this topic. Results are conflicted, with some showing that FC has poor diagnostic accuracy in predicting relapse (14) and no correlation being noted between FC and pMayo score and Harvey Bradshaw Index (15); however, the sensitivity and specificity of FC in determining disease activity were 81.8% and 80.7%, respectively (14) . In the study by Huang et al. (16) 17 pre-conception and pregnant IBD subjects were enrolled, and they found that FC concentration was higher in clinically active disease and in UC patients throughout pregnancy as well. In a prospective Israeli study (17) with over 80 samples from pregnant IBD patients, FC correlated with CDAI and pMayo score. Interestingly, CDAI score correlated weakly with ESR and CRP in the CD group; however, for those with inflammatory presentation, the correlation became more significant. Of note, the same work group previously reported on the limitation of using FC; they found no correlation between FC and clinical scores as well as between albumin levels and inflammatory serum parameters (15) . The influence of pregnancy on symptoms as well as the physiological effects of pregnancy on serum parameters should also be taken into consideration when assessing clinical activity indices. Correia et al. (7) established that FC concentration did not differ during the trimesters of pregnancy; in addition, FC showed no correlation with clinical scores, albumin levels, ESR, and CRP levels.
The main limitation of this study was the low number of pregnant subjects when subdivided in trimesters; however, to our knowledge, this is the first full paper that assesses FC in healthy pregnant women. To summarize, our results revealed that FC concentration did not change during pregnancy in healthy women; by contrast, it elevated in active IBD, suggesting that FC may be a useful noninvasive marker for controlling disease activity in pregnant IBD patients, if CRP is not elevated. Nevertheless, further studies are needed to examine the prognostic role of FC and influential factors on FC in pregnant women with IBD.
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